| Treating myocardial infarction in the post-GUSTO era. A European perspective. | |
| | |
MedLine Citation:
|
PMID: 10174309 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In recent years, thrombolysis has been established as the treatment of choice for patients with evolving myocardial infarction. Reperfusion of ischaemic myocardium through reopening of the occluded infarct-related vessel results in limitation of infarct size and reduction of morbidity and mortality. The landmark Global Utilisation of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO-I) study, published in 1994, has identified a patent infarct vessel as the key to success of treatment. Opening the infarct vessel by means of coronary angioplasty or percutaneous transluminal coronary angioplasty (PTCA) was believed to be dangerous, expensive and ineffective and was only considered as an alternative when contraindications for thrombolytic treatment were present. However, recent reports from centres with experience in performing coronary angioplasty demonstrated superior results of primary coronary angioplasty (without additional or concomitant thrombolytic therapy) with regard to survival, morbidity and cost effectiveness, when compared with thrombolytic therapy. In hospitals with interventional cardiology facilities throughout Europe, this has resulted in a different attitude towards the treatment of patients with myocardial infarction. In a rapidly increasing number of European heart centres, primary coronary angioplasty is applied to reopen infarct vessels. This article tries to summarise the rationale for this approach. |
| | |
Authors:
|
M J de Boer; F Zijlstra |
Related Documents
:
|
15109229 - Angioplasty or stenting of extra- and intracranial vertebral artery stenoses. 2146379 - Xecl excimer laser coronary angioplasty: a convergence of favourable factors. 8421339 - Transcutaneous ultrasonography can be used to guide and monitor balloon angioplasty. 9703569 - Successful balloon angioplasty of a coarctation in an infant <500 g. 11597359 - Alterations of myocardial ultrasonic tissue characterization by coronary angioplasty in... 15949739 - Experience of percutaneous coronary intervention in the management of pediatric cardiac... 17151819 - The use of human heart-type fatty acid-binding protein as an early diagnostic biochemic... 7123109 - Ergonovine test in coronary disease. 2368609 - Influence of pretreatment on interstitial and intracellular space of canine left-ventri... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: PharmacoEconomics Volume: 12 ISSN: 1170-7690 ISO Abbreviation: Pharmacoeconomics Publication Date: 1997 Oct |
Date Detail:
|
Created Date: 1997-11-26 Completed Date: 1997-11-26 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 9212404 Medline TA: Pharmacoeconomics Country: NEW ZEALAND |
Other Details:
|
Languages: eng Pagination: 427-37 Citation Subset: T |
Affiliation:
|
Department of Cardiology, Ziekenhuis de Weezenlanden, Zwolle, The Netherlands. menko.jan.de.boer@tip.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Europe Fibrinolytic Agents / therapeutic use* Humans Myocardial Infarction / therapy* Streptokinase / therapeutic use* Tissue Plasminogen Activator / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; EC 3.4.-/Streptokinase; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Incidence of electrocardiographic changes during cytapheresis using an intermittent flow centrifuge,...
Next Document: Anaemia of prematurity. Epidemiology, management and costs.